Irritable bowel syndrome: Update on pathogenesis and management

Medical Principles and Practice

Volumn 11, Issue 1, 2002, Pages 2-17

  Alaradi, Osama ^a   Barkin, Jamie S ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Brain gut interaction; Constipation; Diarrhea; Enteric nervous system; Irritable bowel syndrome; Motor function; Rome criteria; Sensory function; Serotonin; Visceral hyperalgesia

Indexed keywords

ALOSETRON; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ATROPINE PLUS DIPHENOXYLATE; CIMETROPIUM; CISAPRIDE; CODEINE; DESIPRAMINE; DICYCLOVERINE; DIPHENOXYLATE; DOXEPIN; LOPERAMIDE; MEBEVERINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NARCOTIC AGENT; OTILONIUM BROMIDE; PINAVERIUM; PRUCALOPRIDE; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TEGASEROD; TRAMIMPRAMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMEBUTINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AFFECTIVE NEUROSIS; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONSTIPATION; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIARRHEA; DIETARY FIBER; DIETARY INTAKE; DIGESTIVE SYSTEM FUNCTION DISORDER; DOCTOR PATIENT RELATION; DRUG APPROVAL; DRUG INDUCED DISEASE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT FUNCTION; HEART DISEASE; HUMAN; HYPERALGESIA; INTESTINE INNERVATION; IRRITABLE COLON; ISCHEMIC COLITIS; MENTAL STRESS; META ANALYSIS; MOTOR DYSFUNCTION; PATHOGENESIS; PATHOPHYSIOLOGY; PSYCHIATRIC TREATMENT; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RECEPTOR SENSITIVITY; REGULATORY MECHANISM; REVIEW; SENSATION; SENSORY DYSFUNCTION; WELLBEING;

ABDOMINAL PAIN; AUTONOMIC NERVOUS SYSTEM; COLONIC DISEASES, FUNCTIONAL; CONSTIPATION; DIARRHEA; FEMALE; HUMANS; MALE; PSYCHOPHYSIOLOGIC DISORDERS; PSYCHOTHERAPY; SENSATION DISORDERS;

EID: 0036118814     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048654     Document Type: Review

References (124)

1. Diagnostic approach to the patient with irritable bowel syndrome
2. Irritable bowel syndrome: Disease definition and symptom description
3. Irritable bowel syndrome - A technical review for practice guideline development
4. Diagnostic criteria for the irritable bowel syndrome
5. The functional gastrointestinal disorders and the Rome II process
6. Irritable bowel syndrome: New pharmaceutical approaches to treatment
7. U.S. householder survey of functional gastrointestinal disorders: Prevalence, sociodemography, and health impact
8. Epidemiology of colonic symptoms and the irritable bowel syndrome
9. Irritable bowel-type symptoms in HMO examinees: Prevalence, demographics and clinical correlates
10. Irritable bowel syndrome defined by factor analysis: Gender and race comparisons
11. Review article: Irritable bowel syndrome
12. Pepticulcer, non-ulcer dyspepsia and irritable bowel syndrome in the Netherlands and Japan
13. Functional bowel disorders in apparently healthy Chinese people
14. A study of irritable bowel syndrome diagnosed by Manning criteria in an African population
15. Irritable bowel syndrome in a community: Symptom subgroups, risk factors and health care utilization
16. Irritable bowel syndrome in office based practice in the United States
17. Epidemiology of irritable bowel syndrome in the United States
18. Survey of the AGA membership relating to patients with functional gastrointestinal disorders
19. Irritable bowel syndrome: A multibillion-dollar problem
20. Medical costs in community subjects with irritable bowel syndrome
21. Brain-gut interactions: Implications for newer therapy
22. Fundamentals of neurogastroenterology
23. Principles of applied neurogastroenterology: Physiology/ motility-sensation
24. Regulation of intestinal mast cells and luminal protein release by cerebral thyrotopin-releasing hormone in rats
25. Stress-induced visceral hypersensitivity to rectal distension in rats: Role of CRF and mast cells
26. Mast cell degranulation induces delayed rectal allodynia in rats: Role of histamine and 5-HT
27. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: Cohort study
28. The role of psychological and biological factors in postinfective gut dysfunction
29. Review article: Roles played by 5-hydroxytryptamine in the physiology of the bowel
30. Serotonin: A mediator of the brain-gut connection
31. The enteric nervous system
32. Different pathophysiological functions of the 5-HT4 and 5-HT3 receptors in small and large intestine
33. Therapeutic applications of 5-HT4 receptor agonists and antagonists
34. 5-Hydroxytryptamine-4 receptor agonists initiate the peristaltic reflex in human, rat and guinea pig intestine
35. 5-Hydroxytryptamine and functional bowel disorders
36. Motility disorders and stress
37. Irritable bowel syndrome: Physiological and psychological differences between diarrhea-predominant and constipation-predominant patients
38. Postprandial colonic transit and motor activity in chronic constipation
39. Irritable bowel syndrome: Relationship of disorders in the transit of a single solid meal to symptom patterns
40. Effect of anger on colon motor and myoelectric activity in irritable bowel syndrome
41. Pontine regulation of pelvic viscera: Pharmacological target for pelvic visceral dysfunctions
42. Enhanced perception of physiological intestinal motility in the irritable bowel syndrome
43. Tolerance for rectosigmoid distension in irritable bowel syndrome
44. Anorectal manometry in irritable bowel syndrome: Differences between diarrhea and constipation predominant subjects
45. Basic and clinical aspects of visceral hyperalgesia
46. Altered rectal perception is a biological marker of patients with irritable bowel syndrome?
47. Is rectal pain sensitivity a biological marker for irritable bowel syndrome? Psychological influences on pain perception
48. Site of pain from the irritable bowel
49. The 5-HT3 receptor antagonist alosetron inhibits the colorectal distension-induced depressor response and spinal c-fos expression in the anaesthetised rat
50. Review article: The hypersensitive gut - Peripheral kappa agonists as a new pharmacological approach
51. The kappa agonist fedotozine relieves hypersensitivity to colonic distension in patients with irritable bowel syndrome
52. Regional cerebral activity in normal and pathological perception of visceral pain
53. Intestinal and extraintestinal symptoms in functional gastrointestinal disorders
54. Psychosocial aspects of the functional gastrointestinal disorders
55. Effects of stressful life events on bowel symptoms: Subjects with irritable bowel syndrome compared with subjects without bowel dysfunction
56. Functional abdominal pain, psychiatric illness, and life events
57. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction
58. The irritable bowel syndrome and psychiatric disorder in the community: Is there a link?
59. Symptoms of psychological distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples
60. Psychosocial aspects of functional gastrointestinal disorders
61. Sexual and physical abuse and gastrointestinal illness. Review and recommendations
62. Health status by gastrointestinal diagnosis and abuse history
63. Towards positive diagnosis of the irritable bowel
64. Gastrointestinal symptoms in the irritable bowel syndrome compared with peptic ulcer and inflammatory bowel disease
65. Diagnostic value of the Manning criteria in irritable bowel syndrome
66. Evaluation of Manning criteria in the diagnosis of irritable bowel syndrome
67. Manning criteria in irritable bowel syndrome: Its diagnostic significance
68. Gender differences in Manning criteria in the irritable bowel syndrome
69. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease
70. Irritable bowel syndrome: Definition, diagnosis and epidemiology
71. Irritable bowel syndrome. Still far from a positive diagnosis
72. Kruis scoring system and Manning's criteria in diagnosis of irritable bowel syndrome: Is it better to use combined?
73. Functional bowel disease and functional abdominal pain
74. Functional bowel disorders and functional abdominal pain
75. Gastrointestinal symptom cluster into distinct upper and lower grouping consistent with the Rome classification: A three country population-based study
76. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome
77. Non-colonic features of irritable bowel syndrome
78. Multisystem complaints in patients with the irritable bowel syndrome and functional dyspepsia
79. Functional somatic syndromes: One or many?
80. Redefining abdominal syndromes. Results of a population-based study
81. Identification of distinct upper and lower gastrointestinal symptom grouping in an urban population
82. Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination
83. The irritable bowel syndrome: Mechanisms and a practical approach to management
84. Is rectal biopsy necessary in irritable bowel syndrome?
85. Irritable bowel syndrome: Prognosis and diagnostic safety. A 5-year follow-up study
86. Functional bowel disorders and functional abdominal pain
87. Controlled treatment trials in the irritable bowel syndrome: A critique
88. Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized controlled trials
89. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome?
90. Effect of wheat bran on weight of stool and gastrointestinal transit time: A meta-analysis
91. Double-blind study of ispaghula in irritable bowel syndrome
92. Irritable bowel patients and their long-term response to a high-fiber diet
93. Bran and irritable bowel syndrome: Time for reappraisal
94. 'Prokinetic' treatment of constipation-predominant irritable bowel syndrome: A placebo-controlled study of cisapride
95. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome
96. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation
97. Tegaserod accelerates ororectal transit in patients with constipation-predominant irritable bowel syndrome
98. Tegaserod, a 5HT4 receptor partial agonist relieves key sympotms of irritable bowel syndrome (IBS)
99. Effect of a novel prokinetic drug, R093877, on gestrointestinal transit in healthy volunteers
100. Effect of pucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers
101. Irritable bowel syndrome: New agents targeting serotonin receptor subtypes
102. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder
103. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome
104. Colonic tone and motility in patients with irritable bowel syndrome
105. Therapeutic approach to the patient with irritable bowel syndrome
106. Role of loperamide and placebo in management of irritable bowel syndrome
107. Loperamide in treatment of irritable bowel syndrome - A double-blind placebo-controlled study
108. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist
109. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients
110. Ischemic colitis during treatment with alosetron
111. Management of the irritable bowel syndrome
112. The use of dietary fiber in the management of simple, childhood idiopathic recurrent abdominal pain: Results in a prospective double-blind randomized controlled trial
113. Is bran efficacious in irritable bowel syndrome? A double blind, placebo-controlled crossover study
114. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
115. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride)
116. Alosetron, a 5HT3 antagonist, is effective in the treatment of female irritable bowel syndrome patients
117. Psychological treatment for irritable bowel syndrome: A critique of controlled treatment trials
118. A controlled trial of psychological treatment for the irritable bowel syndrome
119. Diagnosing and treating patients with refractory functional gastrointestinal disorders
120. Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity
121. Antidepressants for functional gastrointestinal syndromes
122. Treatment of functional gastrointestinal disorders with antidepressant medications: A meta-analysis
123. Selective serotonin reuptake inhibitors: Pharmacologic profiles and potential therapeutic distinctions